Zurcher Kantonalbank Zurich Cantonalbank Lowers Holdings in Catalent, Inc. (NYSE:CTLT)

Zurcher Kantonalbank Zurich Cantonalbank decreased its position in shares of Catalent, Inc. (NYSE:CTLT - Free Report) by 58.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 34,681 shares of the company's stock after selling 48,781 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank's holdings in Catalent were worth $1,558,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in CTLT. Gladius Capital Management LP bought a new position in Catalent during the 3rd quarter worth approximately $28,000. Exchange Traded Concepts LLC bought a new stake in shares of Catalent in the 3rd quarter valued at $31,000. Cary Street Partners Investment Advisory LLC increased its stake in shares of Catalent by 1,162.3% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 770 shares of the company's stock valued at $35,000 after acquiring an additional 709 shares in the last quarter. PFG Private Wealth Management LLC bought a new stake in shares of Catalent in the 3rd quarter valued at $155,000. Finally, V Square Quantitative Management LLC bought a new stake in shares of Catalent in the 3rd quarter valued at $181,000.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on CTLT. StockNews.com began coverage on shares of Catalent in a research note on Friday, April 19th. They issued a "sell" rating for the company. Royal Bank of Canada reiterated a "sector perform" rating and issued a $63.50 price objective on shares of Catalent in a research note on Tuesday, February 20th. Stephens reiterated an "equal weight" rating and issued a $63.50 price objective on shares of Catalent in a research note on Thursday, April 4th. Barclays upped their price objective on shares of Catalent from $45.00 to $47.00 and gave the stock an "equal weight" rating in a report on Thursday, January 25th. Finally, UBS Group restated a "neutral" rating and set a $63.50 price objective (up previously from $58.00) on shares of Catalent in a report on Tuesday, February 6th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $52.46.

Catalent Stock Performance

CTLT traded up $0.12 during trading on Friday, hitting $55.92. 2,751,233 shares of the company traded hands, compared to its average volume of 2,545,075. The firm has a market cap of $10.12 billion, a P/E ratio of -8.21, a price-to-earnings-growth ratio of 6.04 and a beta of 1.20. The stock's fifty day moving average is $56.73 and its 200 day moving average is $48.58. The company has a quick ratio of 1.73, a current ratio of 2.48 and a debt-to-equity ratio of 1.34. Catalent, Inc. has a one year low of $31.45 and a one year high of $60.20.

Catalent (NYSE:CTLT - Get Free Report) last posted its quarterly earnings results on Friday, February 9th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.22). The company had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.01 billion. Catalent had a negative net margin of 29.91% and a negative return on equity of 2.43%. Catalent's quarterly revenue was down 10.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.62 EPS. As a group, equities analysts predict that Catalent, Inc. will post 0.28 EPS for the current fiscal year.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.